N-{2-[2-(2-Chloroethoxy)ethoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-YL}acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-{2-[2-(2-Chloroethoxy)ethoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-YL}acetamide
• 英文别名: N-[2-[2-(2-chloroethoxy)ethoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• 化学式: C₁₂H₂₂ClNO₇
• mdl: MFCD01118853
• 分子量: 327.76
• InChiKey: WFEKKWDRJPGTBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Glycotargeting therapeutics
  申请人：École Polytechnique Fédérale de Lausanne (EPFL)

  公开号：US10940209B2

  公开（公告）日：2021-03-09

  Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

  本公开的几个实施方案涉及糖靶向治疗药物，可用于治疗移植排斥、自身免疫性疾病、食物过敏和针对治疗剂的免疫反应。 在几个实施方案中，组合物被配置为靶向肝脏并递送需要耐受的抗原。 本文还公开了组合物诱导免疫耐受的方法和用途。
• GLYCOTARGETING THERAPEUTICS
  申请人：École Polytechnique Fédérale de Lausanne (EPFL)

  公开号：US20170007708A1

  公开（公告）日：2017-01-12

  Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
• [EN] GLYCOTARGETING THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES DE GLYCOCIBLAGE
  申请人：ECOLE POLYTECHNIQUE FED LAUSANNE EPFL

  公开号：WO2017046652A1

  公开（公告）日：2017-03-23

  Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.